Spruce Biosciences is cutting over half of its employees as it looks to secure accelerated approval of a Sanfilippo syndrome therapy it recently acquired from BioMarin.
Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset